|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Androgen and prostatic stroma显示文摘Aim:To investigate the effect of androgen on the proliferation,differentiation and regression of canine prostatic stromal cells in vivo and human stromal cells in vitro.Methods:Twenty-two dogs,including 15 normal prostate doge and 7 prostatic hyperplasia dogs,had their serum concentration of testosterone and estrodiol determined by radioimmunoassay before and after castration.The expression of androgen receptor(AR)and estrogen receptor(ER)in the prostate were analysed by immunohistochemistry and semi-quantitative RT-PCR before and after castration.Light microscopy,transmission electron microscopy and TUNEL assay were carried out successively before and after castration to evaluate the prostatic histomorphology.In vitro serum-free cell cultures from human prostatic stroma were established and exposed to dihydrotestosterone(DHT).The proliferation of the cell culture was detected by MTT assay.The expression of TGFβ bFGF,AR,and smooth muscle cell(SMC) specific proteins (myosin and/or smoothelin)were detected using immunohistochemistry and RT-PCR.The differentiation from fibroblasts to smooth muscle cells was deduced by measuring the expression of SMC specific proteins.Results:Before castration,the serum concentrations of testosterone and estrodiol were not statistically different between normal and hyperplasia groups.Following castration,the serum concentration of testerone decreased rapidly in 2 days,and the concentration of estrodiol had no significant change compared with the pre-castration data.In the prostate,AR was presented in both the epithelial and stromal cells and the AR mRNA level was higher in hyperplasia than in normal prostate tissues(P<0.05).While ER predominantly existed in the prostate stromal cells and the ER mRNA had no difference between the hyperplasia and the normal group.Within the early phase of castration( | Yuan-Jie NIU, Teng-Xiang MA, Ju ZHANG, Yong XU, Rui-Fa HAN, Guang SUNDepartment of Prostatic Disease, Tianjin Institute of Urologial Surgery, Tianjin Medical University,Tianjin 300211, China | 2003 | Asian Journal of Andrology2003，5，1： | 11 |
| 2 | PSA density in the diagnosis of prostate cancer in the Chinese population: results from the Chinese Prostate Cancer Consortium显示文摘We performed this study to investigate the diagnostic performance of prostate-specific antigen density(PSAD)in a multicenter cohort of the Chinese Prostate Cancer Consortium.Outpatients with prostate-specific antigen(PSA)levels≥4.0 ng ml^(-1) regardless of digital rectal examination(DRE)results or PSA levels<4.0 ng ml^(-1)and abnormal DRE results were included from 18 large referral hospitals in China.The diagnostic performance of PSAD and the sensitivity and specificity for the diagnosis of prostate cancer(PCa)and high-grade prostate cancer(HGPCa)at different cutoff values were evaluated.A total of 5220 patients were included in the study,and 2014(38.6%)of them were diagnosed with PCa.In patients with PSA levels ranging from 4.0 to 10.0 ng ml^(-1),PSAD was associated with PCa and HGPCa in both univariate(odds ratio[OR]=45.15,P<0.0001 and OR=25.38,P<0.0001,respectively)and multivariate analyses(OR=52.55,P<0.0001 and OR=26.05,P<0.0001,respectively).The areas under the receiver operating characteristic curves(AUCs)of PSAD in predicting PCa and HGPCa were 0.627 and 0.630,respectively.With the PSAD cutoff of 0.10 ng ml^(-2),we obtained a sensitivity of 88.7%for PCa,and nearly all(89.9%)HGPCa cases could be detected and biopsies could be avoided in 20.2%of the patients(359/1776 cases).Among these patients who avoided biopsies,only 30 cases had HGPCa.We recommend 0.10 ng ml^(-2) as the proper cutoff value of PSAD,which will obtain a sensitivity of nearly 90%for both PCa and HGPCa.The results of this study should be validated in prospective,population-based multicenter studies. | Zi-Jian Song Jin-Ke Qian Yue Yang Han-Xiao Wu Mao-Yu Wang Si-Yuan Jiang Fu-Bo Wang Wei Zhang Rui Chen Chinese Prostate Cancer Consortium | 2021 | Asian Journal of Andrology2021，23，3： | 7 |
| 3 | Volumetric modulated arc radiotherapy : comparison with intensity- modulated radiotherapy and three- dimensional conformal radiotherapy 显示文摘 | Palma D Vollans E James K therapy for delivery of prostate | 2008 | Int J Radiat Oncol Biol Phys2008，72，： | 1 |
| 4 | Immediate versus deferred treatment for advanced prostatic cancer:initial results of the Medical Research Council Trial显示文摘 | The Medical Research Council Prostate Cancer Working Party Investigators Group | 1997 | Br J Urol1997，79，2： | 1 |
| 5 | Maximum androgen blocked in advanced p rostate cancer:an overview of the randomized trials显示文摘 | Prostate Cancer Trialists Collaborative Group | 2000 | Lancet2000，355，9214： | 1 |
| 6 | Prostate Cancer Trialists' Collaborative Group显示文摘 | Maximum androgen blockade in advanced prostate cancer: an overview of the randomized trials | 2000 | Lancet2000，355，9214： | 1 |
| 7 | Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prosPective studies 显示文摘 | Endogenous Hormones and Prostate Cancer Collaborative Group Roddam AW Allen NE | 2008 | J Natl Cancer Inst2008，100，3： | 1 |
| 8 | The Veterans Affairs Cooperarive Study Group on Transurethral Eessection of the Prostate显示文摘 | Wasson JH geda DJ Bruskewitz RC A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia | 1995 | New Engl J Med1995，332，： | 1 |
| 9 | Maximum androgen blockade in advanced Prostate Cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients 显示文摘 | Prostate Cancer trialists Collaborative Group | 1995 | Lancet1995，346，8970： | 1 |
| 10 | Estrogen and prostatic disease显示文摘 | International prostate health council study group | 2000 | Prostate2000，45，： | 1 |
| 11 | Maximum androgen blocked in advanced prostate cancer: an overview of the randomized trials显示文摘 | Prostate Cancer Trialists Collaborative Group | 2000 | Lancet2000，355，9214： | 1 |
| 12 | Clin Genitourin Cancer显示文摘 | Goodman OB Jr Symanowski JT Loudyi A Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer | 2011 | 9( 1 ) :31-382011，9，1： | 1 |
| 13 | Maximum androgen blocked in advanced prostate cancer:an overview of the randomized trials显示文摘 | Prostate cancer trialist's collaborative group | 2000 | Lancet2000，355，9214： | 1 |
| 14 | Maximum androgen blocked in advanced prostate cancer: an overview of the randomized trials 显示文摘 | Prostate Cancer Trialist's Collaborative Group | 2000 | Lancet2000，355，： | 1 |
| 15 | Prostate Cancer Trialists' Collabo-rative Group显示文摘 | Maximum androgen blockade in advanced prostate cancer:an overview of the random ised trials | 2000 | Lancet2000，355，： | 1 |
| 16 | Maximun androgen blockade in advanced prostate cancer: an overview of the randomized trials显示文摘 | Prostate Cancer Trialists'Collaborative Group | 2000 | Lancet2000，355，7： | 1 |
| 17 | Expression and of metallothionein mRNA levels in the of noble rats: lack of expression in the ventral prostate and regulation by sex hormones in the dorsolateral pruslate显示文摘 | Chalak S O regulation prostates liveria P Kaplan P | 1996 | Prostate1996，29，2： | 1 |
| 18 | 2显示文摘 | DONG JT LAMB PW RINKER SCHAEFFER CW et aL KAI1 a metastasis suppressor gene for prostate cancer on human chromosome llpll | 1995 | Science1995，268，5212： | 1 |
| 19 | The Leuprolide Study Group显示文摘 | Leuprolide versus diethylstilbestrol for metastatic prostate cancer | 1984 | N Engl J Med1984，311，： | 1 |
| 20 | The Leuprolide Study Group显示文摘 | Leuprolide versus diethylstilbestrol for metastatic prostate cancer | 1984 | N Engl J Med1984，311，20： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员